Kamada Ltd KMDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Kamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High Year
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026
Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026
Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel
Sidoti Events, LLC's September Small-Cap Virtual Conference
CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
Trading Information
- Previous Close Price
- $8.11
- Day Range
- $8.05–8.22
- 52-Week Range
- $6.60–9.35
- Bid/Ask
- $8.18 / $8.23
- Shares Outstanding
- 57.73M
- Market Cap
- $471.09M
- Volume/Avg
- 74,668 / 130,971
Key Statistics
- Price/Earnings (Normalized)
- 20.75
- Price/Sales
- 2.48
- Dividend Yield (Trailing)
- 2.08%
- Dividend Yield (Forward)
- 2.08%
- Dividend Payment Schedule
- Apr, Sep
- Total Yield
- 2.08%
Company Profile
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 462
- Website
- https://www.kamada.com
Valuation
Metric | KMDA |
|---|---|
Price/Earnings (Normalized) | 20.75 |
Price/Book Value | 1.79 |
Price/Sales | 2.48 |
Price/Cash Flow | 10.30 |
Price/Earnings
KMDA
Financial Strength
Metric | KMDA |
|---|---|
Quick Ratio | 2.24 |
Current Ratio | 4.17 |
Interest Coverage | — |
Quick Ratio
KMDA
Profitability
Metric | KMDA |
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
KMDA
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|!Q%NLlC$ | LOCK|L>^G> | $72B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|Yw^%&@S | LOCK|CDs? | $49B | |||
| Haleon PLC ADR HLN | LOCK|Znq#LqK | LOCK|ys | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|Zr^@^?V | LOCK|Rr& | $34B | |||
| Viatris Inc VTRS | LOCK|b@<k<X& | LOCK|j?W | $23B | |||
| Elanco Animal Health Inc ELAN | LOCK|vdL | LOCK|gMV | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|F<F?pb | LOCK|V&> | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|@#@>VCV | LOCK|%J | $4B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|&<$@fm | LOCK|$!Bkq | $2B | |||
| Perrigo Co PLC PRGO | LOCK|?$%f!^s | LOCK|<^k | $2B |